Transaction · 0001882909-26-000004

Calvin Sandra

Calvin Sandra, SVP, CAO, reported a transaction classified as exercise at Travere Therapeutics, Inc. involving 2500.000000 shares for an estimated $68750.00. Reported holdings after the transaction were 44853.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MSVP, CAO
TVTXTravere Therapeutics, Inc.
Trade date
Sep 15, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value$68.7kShares × reported price
Shares traded2.50k$27.50 per share
Holdings after44.8kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TVTX price since this filing

Daily closing prices, with the filing date and available return windows
TVTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -1.0%1w ago +5.3%1d ago +4.8%
Returns since7d -5.3%30d -21.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001882909-26-000004
Common Stock
Transaction date
Sep 15, 2026
Filed Sep 18, 2026, 01:29 AM · 3d delay
Shares
2,500 sh
$27.50 per share
Estimated value
$68.7k
Computed from shares × price
Holdings after
44,853 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SVP, CHIEF ACCOUNTING OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

  2. F2

    The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of t…

  3. F3

    The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of…

  4. F4

    The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of…

  5. F5

    The stock option is fully vested and exercisable.

  6. F6

    One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereaft…

  7. F7

    One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereaft…

Original filing · 0001882909-26-000004
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TVTX